Immuron Ltd increased full-year Revenue by A$426,599, or 6%, to A$7,713,601, driven primarily by stronger Travelan sales in Australia and the United States. The company expects Travelan revenue to continue rising, while it identifies funding, profitability and product-development uncertainty as principal risks for investors.
Key Highlights
- Full-year revenue from customer contracts reached A$7,713,601.
- The Australian R&D tax incentive refund was recognized as A$782,313.
- Immuron reported accumulated losses of A$84,970,154 at June 30, 2026.
Immuron Ltd (NASDAQ: IMRN) increased full-year revenue to A$7,713,601 for the year ended June 30, 2026, a rise of A$426,599, or 6%, from A$7,287,002. The increase was primarily linked to growth in Australian and U.S. markets for Travelan®. Immuron expects revenue from Travelan sales to continue increasing. The company also recognized A$1,169,869 in total other income during the year. Its stated risks include funding and profitability, commercial and clinical-stage uncertainty, eligibility of Australian Research and Development tax refunds, limitations on tax-loss utilization, potential Foreign Corrupt Practices Act violations and the possible loss of Foreign Private Issuer status.
Travelan Drives Revenue Growth
Revenue from contracts with customers rose from A$7,287,002 to A$7,713,601 over the two fiscal years. Immuron attributed the movement mainly to higher Travelan sales in Australia and the United States. Travelan is the company’s commercial over-the-counter product. Immuron also researches and clinically develops products principally intended for travelers’ diarrhea and Clostridioides difficile infections, while the filing identifies IMM-124E as a current lead product candidate that has not been sufficiently advanced to market or generate commercial revenue. The company describes itself as both commercial-stage and development-stage. Other than Travelan, its products have not sufficiently progressed to commercial application or revenue generation. Immuron states that successful development of current or future candidates may still Fail to produce sufficient or sustainable revenue for profitability.
Other Income Changes
Australian R&D tax incentive income totaled A$782,313 for the year, compared with A$1,110,577 in the prior fiscal year. Immuron said eligible Australian research and development spending decreased during the period, reducing the related accrued refund. Eligible spending increased for IMM-529, which concerns Clostridioides difficile infection, and for IMM-124E work involving Manufacturing processes and colostrum harvest and collection methods. Ineligible spending on an overseas IMM-124E clinical trial decreased. The company recognized A$339,819 from a Henry M Jackson Foundation R&D grant, up from A$124,164. No income was recognized from the Medical Technology Enterprise Consortium grant, compared with A$146,252 previously. Other income was A$47,737, versus A$30,512. Immuron recognized a receivable of A$782,313 for the year.
Travelan Outlook Remains Positive
Immuron’s expected-results discussion sets out a two-part approach. The company expects Travelan sales revenue to keep increasing. Immuron has incurred cumulative losses and negative operating cash flows since its inception in 1994. Accumulated losses stood at A$84,970,154 at June 30, 2026.
Funding And Development Risks
Immuron says it may need additional funding to continue operations if product sales do not lead to profitability. It also identifies uncertainty around commercial and clinical development, including whether product candidates can reach the market and produce sustainable revenue. Use of those losses depends on satisfying applicable ownership or same-business tests, and losses from different jurisdictions can only offset profits in the relevant jurisdictions. U.S. net operating losses and research and development credits may face annual limits under ownership-change provisions. The company’s U.S. carry-forward net operating losses first begin expiring in 2035. Immuron also says its operations may be subject to the U.S. Foreign Corrupt Practices Act and similar laws. Potential criminal or civil penalties from violations could adversely affect results, financial condition and cash flows. Loss of Foreign Private Issuer status is another identified risk.



Please wait processing your request...